Loratadine exclusivity
This article was originally published in The Tan Sheet
Executive Summary
Andrx "will accept Wyeth's offer to forsake generic exclusivity" after Aug. 9 and requests FDA adopt "appropriate measures to implement Wyeth's offer" in March 21 comments. In a recent citizen petition, Andrx alleged marketing exclusivity for Wyeth's generic loratadine should start from the Alavert approval date, although Wyeth disputed the assertion (1"The Tan Sheet" March 31, 2003, p. 9). While Andrx accepts Wyeth's "compromise," firm maintains Wyeth's position "cannot be right," because firm "implicitly concedes as much by offering to forsake generic exclusivity 180 days after a date that is before the date on which it will commence" marketing of generic loratadine...
You may also be interested in...
Wyeth Loratadine Exclusivity Should Reflect Alavert Approval Date – Andrx
Marketing exclusivity for Wyeth Consumer Healthcare's generic loratadine tablets should begin on "the date on which Wyeth began marketing generic loratadine in its product Alavert," rival marketer Andrx asserts in a Feb. 27 citizen petition
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.